Surreal illustration of the interaction between the colon and CMV virus.

Ulcerative Colitis and CMV: What You Need to Know About the Link

Mira Elwood in Health & Wellness December 2025 • 4 min read.

"A deeper look into how cytomegalovirus (CMV) affects ulcerative colitis (UC) patients, and why early detection is crucial for long-term health."

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the innermost lining of the large intestine (colon) and rectum. While the exact cause of UC isn't fully understood, it's believed to involve a combination of genetic predisposition, immune system dysfunction, and environmental factors. Managing UC often requires long-term immunosuppressive therapy to control inflammation, which can sometimes lead to other complications, such as viral infections.

One such virus that has gained attention in the context of UC is cytomegalovirus (CMV). CMV is a common virus that can infect people of all ages. Most healthy adults who contract CMV experience mild flu-like symptoms or no symptoms at all. However, in individuals with weakened immune systems, such as those with UC on immunosuppressive medications, CMV can reactivate and cause more severe problems.

Recent research has explored the link between CMV and UC, suggesting that CMV infection in the colon may be associated with poorer outcomes for UC patients. One study in particular sheds light on how the detection of CMV DNA in the colonic mucosa of UC patients is linked to an increased risk of needing proctocolectomy, a surgical procedure involving the removal of the colon and rectum. Understanding this connection is crucial for better managing UC and improving patient outcomes.

How Does CMV Affect Ulcerative Colitis?

Surreal illustration of the interaction between the colon and CMV virus.

Cytomegalovirus (CMV) is a type of herpes virus that, once it infects a person, remains in their body for life. In people with healthy immune systems, CMV usually stays dormant and doesn't cause any noticeable symptoms. However, certain situations can reactivate the virus, leading to potential health issues. For individuals with ulcerative colitis (UC), this reactivation can complicate their condition.

Here’s why CMV is particularly concerning for those with UC:

Weakened Immunity: UC is often treated with immunosuppressant drugs, which, while controlling the inflammation in the colon, also weaken the body's natural defenses. This makes it easier for CMV to reactivate and cause problems.
Colon Inflammation: The inflammation caused by UC can create an environment in the colon that is conducive to CMV replication. The virus can then contribute to further inflammation, exacerbating the symptoms of UC.
Impaired Response to Treatment: Studies have shown that UC patients with active CMV infections may not respond as well to standard UC treatments. This can lead to prolonged flares and a greater need for more aggressive interventions.

The presence of CMV in the colonic mucosa of UC patients has been linked to several adverse outcomes, including a longer time to achieve steroid-free remission and an increased risk of proctocolectomy. Therefore, early detection and management of CMV are essential for improving the overall health and quality of life for individuals with UC.

The Importance of Ongoing Research

The connection between CMV and ulcerative colitis is a complex and evolving area of research. While current studies provide valuable insights, further prospective, controlled research is needed to fully understand the clinical relevance of CMV in UC patients. By continuing to investigate this relationship, we can refine diagnostic and treatment strategies, ultimately improving the lives of those affected by these conditions.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1007/s00384-018-3210-8, Alternate LINK

Title: The Detection Of The Cytomegalovirus Dna In The Colonic Mucosa Of Patients With Ulcerative Colitis Is Associated With Increased Long-Term Risk Of Proctocolectomy: Results From An Outpatient Ibd Clinic

Subject: Gastroenterology

Journal: International Journal of Colorectal Disease

Publisher: Springer Science and Business Media LLC

Authors: Wiebke Schenk, Tobias Klugmann, Annett Borkenhagen, Chris Klecker, Peter Dietel, Ralf Kirschner, Eckhardt Schneider, Tony Bruns, Andreas Stallmach, Niels Teich

Published: 2018-11-30

Everything You Need To Know

What is the link between Cytomegalovirus (CMV) and Ulcerative Colitis (UC)?

The connection between Cytomegalovirus (CMV) and Ulcerative Colitis (UC) is significant because CMV reactivation can worsen UC outcomes. CMV, a common herpes virus, typically remains dormant in healthy individuals. However, in those with UC, especially when treated with immunosuppressants, the immune system is weakened. This allows CMV to reactivate and cause increased inflammation in the colon, exacerbating UC symptoms and potentially hindering response to standard UC treatments. Research indicates that detecting CMV DNA in the colonic mucosa of UC patients is associated with a greater likelihood of needing a proctocolectomy.

How does the use of immunosuppressive medications affect the relationship between CMV and Ulcerative Colitis?

Immunosuppressive medications, commonly used to manage Ulcerative Colitis (UC), play a crucial role in the CMV-UC relationship. These medications, while effectively controlling inflammation in the colon, simultaneously suppress the body's immune defenses. This weakened state makes it easier for the Cytomegalovirus (CMV), which remains in the body after initial infection, to reactivate. When CMV reactivates in individuals with UC, it can lead to increased inflammation in the colon, potentially worsening UC symptoms and complicating treatment.

What are the potential adverse outcomes for Ulcerative Colitis patients with active CMV infections?

Ulcerative Colitis (UC) patients with active Cytomegalovirus (CMV) infections face several potential adverse outcomes. Research suggests that these patients may experience a prolonged time to achieve steroid-free remission, meaning it takes longer to reduce reliance on steroids. Furthermore, active CMV infections have been linked to an increased risk of proctocolectomy, a surgical procedure involving the removal of the colon and rectum. In essence, the presence of active CMV can worsen the prognosis for UC patients, making effective early detection and management of CMV critical.

Why is early detection of CMV important for Ulcerative Colitis patients?

Early detection of Cytomegalovirus (CMV) is crucial for Ulcerative Colitis (UC) patients because it allows for timely intervention and improved management of the disease. Identifying CMV early enables healthcare providers to implement appropriate treatment strategies, potentially preventing the exacerbation of UC symptoms and mitigating adverse outcomes. For instance, early detection might lead to adjusting UC treatments or initiating antiviral therapy to control the CMV infection, thereby improving the chances of achieving remission and reducing the likelihood of complications like proctocolectomy.

What are the next steps in understanding the CMV and Ulcerative Colitis connection?

The relationship between Cytomegalovirus (CMV) and Ulcerative Colitis (UC) is an area of ongoing research, and the next steps involve further investigation to deepen our understanding. Researchers need to conduct more prospective, controlled studies to comprehensively analyze the clinical significance of CMV in UC patients. This research will enable a refinement of diagnostic and treatment strategies, ultimately aiming to enhance the lives of those affected by both conditions. Furthermore, continued research will help to clarify the optimal approaches for managing CMV infections in UC patients, including the timing and type of antiviral interventions.